You are here:

infliximab 100mg powder for intravenous infusion (Remicade)


following a full submission:

infliximab (Remicade®) is not recommended for use within NHS Scotland for maintenance treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. Infliximab for the treatment of acute severe, active Crohn’s disease was approved by NICE in 2002.

Infliximab maintenance treatment, compared to placebo, is associated with higher rates of clinical remission and a longer time to loss of response in patients with active Crohn’s disease. The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.

Drug Details

Drug Name: infliximab 100mg powder for intravenous infusion (Remicade)
SMC Drug ID: 363/07
Manufacturer: Schering-Plough Ltd
Indication: Severe, active Crohn's disease
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Superseded
Date Advice Published: 7 May 2007

Archived Advice

Full submission 12 July 2004